The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate

NCT02584582 on ClinicalTrials.gov · last registry update 2015-10-22

A small phase 2/phase 3 — 10 participants, against a typical 60. Its estimated completion date, November 2015, has passed with no update to the record. Primary outcome, as filed: Glucagon concentration (postprandial). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: UNKNOWN
Phase: P2/P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Hvidovre University Hospital
Sponsor type: Other
Enrollment: 10
Started: 2015-07
Primary completion: 2015-11 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Glucagon concentration (postprandial)

Conditions studied

Type 1 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.